Abstract

Bausch Health Companies Inc is scheduled to release first-quarter 2026 results on April 29, 2026 Post Market; investors will focus on whether revenue growth near mid-single digits and earnings per share trends align with guidance amid recent clinical and margin developments.

Market Forecast

The current quarter’s consensus framework points to total revenue of 2.39 billion US dollars, implying year-over-year growth of 5.17%, with forecast EBIT around 0.71 billion US dollars and adjusted EPS near 0.68, reflecting a 17.16% year-over-year decline. There is no explicit company margin outlook disclosed for the quarter in the collected data, so market attention is likely to center on how mix and operating discipline translate into the gross margin trajectory and whether net results improve from loss territory as interest expense and below-the-line items normalize.

Within the business portfolio, management and the market will likely emphasize stability in the Bausch + Lomb/International and Salix franchises, given their scale and earlier revenue baselines, with investors watching pricing elasticity, channel restocking, and foreign exchange effects. The segment with the clearest growth optionality is Solta Medical in medical aesthetics, which generated 137.00 million US dollars last quarter; momentum here depends on procedure demand, capital equipment placements, and consumable utilization rather than patent cliffs, and remains a focal point for incremental upside if execution holds.

Last Quarter Review

In the preceding quarter, Bausch Health Companies Inc reported revenue of 2.80 billion US dollars, a 9.26% year-over-year increase, with a gross profit margin of 71.46%, a GAAP net loss attributable to the parent company of 112.00 million US dollars and a net profit margin of -4.01%, while adjusted EPS was 1.10, down 4.35% year-over-year. A notable financial feature was the combination of high gross profitability and a negative bottom line, highlighting the sensitivity of net results to non-operating items such as interest expense and one-time charges.

From a business-mix perspective, the revenue base was led by the Bausch + Lomb/International unit at 1.71 billion US dollars, followed by Salix at 693.00 million US dollars, Diversified Products at 255.00 million US dollars, and Solta Medical at 137.00 million US dollars; the portfolio structure underpinned strong gross margins, though the earnings translation was constrained by below-the-line headwinds.

Current Quarter Outlook

Main revenue engine: Bausch + Lomb/International and Salix

The path to meeting revenue expectations in the first quarter of 2026 hinges on steadiness in the large, diversified revenue engines—Bausch + Lomb/International and Salix. Taken together, these units accounted for the bulk of last quarter’s sales base, and their sheer scale means mid-single-digit growth at the company level can be achieved if volume and price dynamics remain constructive and if distributor inventory levels are in balance. On the operational side, execution points to watch include reorder cadence post-year-end, the cadence of new prescriptions in promoted brands, and the management of rebates and allowances that can create intra-quarter variability.

Margin conversion for these franchises remains the central debate. Last quarter’s 71.46% gross margin suggests the product mix supports healthy contribution at the manufacturing level, so the determinant of earnings leverage this quarter is likely to be operating expenditures and the burden of non-operating costs. Given the lack of explicit margin guidance in the collected data, investors will triangulate from revenue and EBIT forecasts; the 0.71 billion US dollars EBIT estimate implies modest year-over-year expansion of 0.49%, which, alongside a 5.17% revenue growth forecast, suggests limited operating leverage. Whether this level of EBIT can translate to positive net income depends on the trajectory of interest expense and any special items.

The forecast EPS of approximately 0.68 implies a year-over-year decline of 17.16%, signaling that, even with top-line growth, earnings may be pressured by either higher spend timing, below-the-line charges, or a less favorable mix compared with the prior-year period. Consequently, the quarter’s narrative for these core businesses will center on quality of revenue—sustained demand, pricing integrity, and efficient spend—rather than headline growth alone. If operating discipline enables EBIT to track or exceed forecasts while interest expense stabilizes, there is scope to reduce the gap between gross profit strength and net results.

Most promising growth stream: Solta Medical

Solta Medical, at 137.00 million US dollars in last quarter’s revenue, remains a key focus for growth. Its demand drivers are relatively distinct from prescription therapeutics: utilization rates in energy-based aesthetics, the pace of capital equipment placements, and consumable pull-through all matter as catalysts. The segment’s growth outlook this quarter will be influenced by procedure trends in core geographies and the company’s ability to drive attachment rates and system upgrades in existing installed bases.

Visibility into intra-quarter order trends is typically limited ahead of results, but the attraction of this unit is its potential to contribute incremental margin dollars if volume trends hold and if price/mix remains favorable. Even without formal segment guidance in the gathered data, investors will be looking for signs of momentum—commentary on new product introductions, adoption by key accounts, and geographic expansion—that can offset variability elsewhere in the portfolio. Given the smaller revenue base relative to the lead segments, Solta’s upside impact on consolidated revenue growth may be modest in absolute terms, but incremental contributions can matter for EBIT if operating costs in the segment scale efficiently.

Set against this potential is the need for consistent execution in channel management and marketing. Seasonality, promotional intensity by peers, and clinic capacity utilization can influence quarterly print dynamics. The quarter’s yardstick is whether Solta’s revenue cadence improves sequentially and whether its contribution margins trend up, helping to counteract pressure from other business lines and supporting the company’s effort to align gross margin strength with net earnings performance.

Stock-price swing factors this quarter

Earnings sensitivity to non-operating items is a primary swing factor. The last quarter showed that a negative net margin can emerge despite robust gross profitability when interest expense and one-time items are elevated. For the quarter to be reported, the balance between EBIT delivery and below-the-line charges will likely dictate whether adjusted EPS converges toward the 0.68 forecast or deviates materially. Any update on debt management, refinancing activities, or the timing of discrete expenses could shift sentiment quickly.

Pipeline and R&D updates are another potential swing factor for the stock this quarter, amplified by recent clinical outcomes. Commentary around the development portfolio, especially after phase 3 program developments, may influence expectations for medium-term cash flows and alter the perceived risk-adjusted growth profile. Even if top-line in the quarter aligns with forecasts, incremental disclosures about the shape and prioritization of the pipeline can influence valuation multiples and dictate how investors weigh near-term EBITDA against future optionality.

Operationally, spend discipline and working-capital management will be scrutinized. Inventory levels, receivables collections, and the timing of promotional investments can create near-term noise that impacts cash from operations and the conversion of EBIT to free cash flow. If management demonstrates sequential improvement in operating efficiency without sacrificing core revenue growth, the stock could respond positively even if headline EPS is in line, because investors are highly attuned to the translation of operating profits into sustainable cash generation.

Analyst Opinions

The balance of commentary reviewed in the recent quarter skews cautious, with bearish views outweighing bullish ones in the period leading into April 29, 2026; the prevailing theme emphasizes earnings sensitivity to non-operating costs, the drag from recent clinical outcomes, and the risk that forecast EPS of roughly 0.68 may still prove vulnerable if below-the-line items do not abate. The majority perspective highlights three elements that frame expectations: first, the gap between a high gross margin profile and a negative net margin in the last quarter underscores how leverage and special items can overshadow healthy top-line and manufacturing performance; second, the forecast revenue growth of 5.17% and EBIT growth of 0.49% suggest limited operating leverage in the near term; third, the year-over-year decline of 17.16% in expected EPS points to pressure from factors that may not be fully visible in the revenue line, such as interest, tax, and discrete charges.

Bearish analyses point to the mechanics of earnings translation, arguing that mid-single-digit revenue gains are meaningful but insufficient to guarantee expansion in adjusted earnings if spending and financing costs are not reined in. From this vantage, the quarter’s most important validation point is whether EBIT prints close to 0.71 billion US dollars and whether any unusual items are small enough for adjusted EPS to align with expectations. A shortfall on either dimension could drive downward estimate revisions, particularly if management commentary implies that the underlying dynamics—such as interest expense load or ongoing R&D timing—will persist into subsequent quarters.

The cautious camp also underscores that last quarter’s net loss attributable to shareholders of 112.00 million US dollars reflects the company’s earnings sensitivity to line items beyond gross profit, and this sensitivity may continue to overshadow otherwise solid top-line growth. Accordingly, even if reported revenue approximates 2.39 billion US dollars, sell-side models are likely to emphasize the risk that EPS tracks toward the lower end of a reasonable range unless the company delivers a clear improvement in cost structure or provides visibility into reduced below-the-line drag. This is why many previews frame the setup as one where execution must be tight across operating expenses and working-capital flows to avoid a repeat of the divergence between gross and net performance.

Within this majority view, Solta Medical is acknowledged as a genuine pocket of growth potential, but analysts caution that the aesthetic franchise’s positive contributions may not fully offset variability in larger segments within a single quarter. The principal message is not that Solta lacks momentum; rather, it is that the absolute scale of Solta’s revenue limits its ability to compensate for headwinds elsewhere if those headwinds are meaningful. Hence, while updates on placements, consumable throughput, and commercial initiatives will be welcomed, the quarter’s share-price reaction will likely hinge on consolidated profitability metrics and any color on the trajectory of interest burden.

The bearish consensus further notes that the forecast contraction in adjusted EPS occurs despite forecast growth in revenue and modest EBIT expansion, suggesting deleverage between EBIT and net income. This gap is a central concern and drives a preference among cautious commentators to wait for clearer signs that the bridge from EBIT to net earnings is improving sustainably. They look for signals in guidance language, in management’s commentary on expense phasing, and in any detail on the timing and magnitude of extraordinary items.

For investors parsing this setup, the prevailing takeaway from the majority of opinions is straightforward: results close to revenue estimates will matter, but the quarter’s valuation response will likely be dictated by profitability conversion. If reported gross margin stays resilient and operating expenses are contained such that EBIT meets or slightly exceeds the 0.71 billion US dollars forecast, attention will immediately shift to non-operating items to assess whether EPS can gravitate toward 0.68 without adjustment-heavy reconciliation. Conversely, if EBIT underperforms, or if bottom-line items expand, the stock could face pressure as the market recalibrates the near-term earnings power that underpins the current consensus.

In sum, the majority outlook is cautious: while mid-single-digit revenue growth appears feasible and the core franchises remain sizable enough to support the forecast, the onus is on the company to demonstrate tighter expense control and improve the earnings bridge from gross profit to adjusted EPS. The commentary indicates that conviction will increase if the quarter shows progress on these fronts, aligning top-line delivery with clearer momentum in margins and net results. Until then, the sentiment leans defensive, with price action likely to track the clarity and quality of the earnings print rather than headline revenue growth alone.